All News

Breast cancer incidence rates among non-Hispanic (NH) white women in the United States stabilized between 2003 and 2007 after a sharp decline between 2002 and 2003 that followed a drop in the use of postmenopausal hormone therapy, according to a study published online Feb. 28 in Cancer Epidemiology, Biomarkers & Prevention.

There is a lack of sex-specific data relating to the safety and effectiveness of high-risk cardiovascular devices prior to U.S. Food and Drug Administration approval, according to a review published online March 1 in Circulation: Cardiovascular Quality and Outcomes.

According to government estimates, the incidence of ovarian cancer is almost 13 per 100,000 women per year, and most cases are diagnosed in an advanced stage. As such, proper treatment is critical to ensure survival. However, Dr Melissa M. Thrall, fellow in the department of obstetrics and gynecology at the University of Washington, found that less than 40% of women reliant on Medicare receive standard care.

Primary care physicians are the entry point for care for many patients. They are often responsible for determining when additional expertise is needed and to which specialist a patient should go for additional care. Although studies have shown that gynecologic oncologists can improve surgical and survival outcomes for patients with ovarian cancer, the referral rate from primary care physicians to gynecologic oncologists remains relatively low.

Both patients and physicians can bring qualities to a clinical encounter that result in its being perceived as difficult, and patients involved in these types of encounters have worse short-term outcomes, according to research published online Jan. 25 in the Journal of General Internal Medicine.

Approximately 5% of women who seek medical assistance for menorrhagia from their primary care physicians or gynecologists never make their way to a hematologist, even though many of these women have such underlying hemostatic abnormalities as decreased von Willebrand factor (VWF), platelet dysfunction, and decreased coagulation factors. These women in turn are in danger of experiencing bleeding complications during surgery, childbirth, or other invasive procedures.

In women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, treatment with trastuzumab for one year after chemotherapy is associated with significant disease-free survival at a four-year follow-up, according to a study published online Feb. 25 in The Lancet Oncology.

Escitalopram, a selective serotonin reuptake inhibitor approved by the US Food and Drug Administration for the treatment of anxiety and depression, significantly reduces the frequency, severity, and bother of hot flashes, according to study findings.

In the latest study to attempt to determine whether cigarette smoking increases or decreases a woman's risk for breast cancer, researchers from Harvard University found that active smoking, particularly before giving birth for the first time, modestly increases the risk for the disease.